Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.

Stories

The big-money push for more colon cancer tests

A golfer hits a shot at a 2018 tournament sponsored by Cologuard.
Cologuard, made by Exact Sciences, sponsored a golf tournament this year. Photo: Darren Carroll/Getty Images

Exact Sciences, maker of the colon cancer test Cologuard, has signed a multimillion deal with drug giant Pfizer to increase and share in the costs of marketing the test — a move Wall Street cheered yesterday.

The bottom line: Physicians and other medical professionals should be ready for an onslaught of calls and face-to-face pitches from the companies' sales armies, even though there is evidence the costly Cologuard test can lead to false positives.

Read more toggle
Show less
Go deeper378 Words

The big picture: This marketing blitz inevitably will push more people to get checked for colon cancer, which public health experts say is a good thing. Colon cancer is the second-leading cause of cancer death in the U.S.

But experts also say it will come at a steep price with potentially harmful and wasteful care.

  • A doctor must prescribe Cologuard, an FDA-approved home kit where people mail their stool to a lab for DNA testing.
  • Medicare pays $509 for Cologuard. Most other commercial health insurers cover it, and likely pay more than Medicare.
  • The U.S. Preventive Services Task Force says Cologuard is acceptable for colon cancer screening. But when compared with cheaper tests, Cologuard was tied to "more false-positive results, more diagnostic colonoscopies, and more associated adverse events per screening test," and it "may potentially lead to overly intensive surveillance," according to the USPSTF.
  • "Worried patients and/or providers may feel obligated to order additional tests — which could be imaging or invasive — to determine whether there could be a cancer elsewhere in the body, thus potentially adding to the costs and risks of Cologuard screening," Richard Hoffman, a professor of internal medicine and epidemiology at the University of Iowa, said in an email.
  • An Exact Sciences spokesperson referred to a company-funded study on why it believes Cologuard is better than other tests.

By the numbers: The financial terms of the agreement are lucrative for both sides.

  • Pfizer will spend nearly $70 million in Cologuard marketing and promotion from October through the end of 2021.
  • Exact Sciences will maintain its baseline marketing spend of at least $80 million per year and match Pfizer's additional spending.
  • Any profits that are earned over certain Cologuard revenue thresholds will be split 50-50, and Pfizer can get a royalty of up to 3% of Cologuard sales for three years after the deal ends in 2021.
  • A Pfizer executive told investors it made the deal because it had a sales team for Lyrica, a drug that is losing market exclusivity, that could shift to Cologuard instead.
  • Exact Sciences expects to bring in at least $1.2 billion in Cologuard revenue by 2021.
  • CEO Kevin Conroy made almost $50 million over the past three years, including $32.3 million in 2017.
Cancer screening
More stories loading.